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Abstract
Objective To quantify the accuracy and reproducibility of pathologists’ diagnoses of melanocytic skin lesions.
Design Observer accuracy and reproducibility study.

Setting 10 US states.
Participants Skin biopsy cases (n=240), grouped into sets of 36 or 48. Pathologists from 10 US states were
randomized to independently interpret the same set on two occasions (phases 1 and 2), at least eight months apart.
Main outcome measures Pathologists’ interpretations were condensed into five classes: I (eg, nevus or mild atypia);
II (eg, moderate atypia); III (eg, severe atypia or melanoma in situ); IV (eg, pathologic stage T1a (pT1a) early
invasive melanoma); and V (eg, ≥pT1b invasive melanoma). Reproducibility was assessed by intraobserver and
interobserver concordance rates, and accuracy by concordance with three reference diagnoses.
Results In phase 1, 187 pathologists completed 8976 independent case interpretations resulting in an average of 10
(SD 4) different diagnostic terms applied to each case. Among pathologists interpreting the same cases in both
phases, when pathologists diagnosed a case as class I or class V during phase 1, they gave the same diagnosis in
phase 2 for the majority of cases (class I 76.7%; class V 82.6%). However, the intraobserver reproducibility was
lower for cases interpreted as class II (35.2%), class III (59.5%), and class IV (63.2%). Average interobserver
concordance rates were lower, but with similar trends. Accuracy using a consensus diagnosis of experienced
pathologists as reference varied by class: I, 92% (95% confidence interval 90% to 94%); II, 25% (22% to 28%); III,
40% (37% to 44%); IV, 43% (39% to 46%); and V, 72% (69% to 75%). It is estimated that at a population level,
82.8% (81.0% to 84.5%) of melanocytic skin biopsy diagnoses would have their diagnosis verified if reviewed by a
consensus reference panel of experienced pathologists, with 8.0% (6.2% to 9.9%) of cases overinterpreted by the
initial pathologist and 9.2% (8.8% to 9.6%) underinterpreted.
Conclusion Diagnoses spanning moderately dysplastic nevi to early stage invasive melanoma were neither
reproducible nor accurate in this large study of pathologists in the USA. Efforts to improve clinical practice should
include using a standardized classification system, acknowledging uncertainty in pathology reports, and developing
tools such as molecular markers to support pathologists’ visual assessments.

Introduction
Diagnostic errors contribute to approximately 10% of patient deaths and are the top cause of medical malpractice
payouts.1 A recent report by the National Academies of Sciences, Engineering, and Medicine deemed improvements
in the diagnostic process “a moral, professional, and public health imperative.”1
The goal of a medical diagnosis is to identify and assign natural phenomena to the correct diagnostic classification
with both accuracy and precision. However, inadequate development and inconsistent use of disease labels and
classification schemes by clinicians can lead to patient harm.2 3 While physicians may observe similar features on a
biopsy sample slide or radiograph or on a patient’s physical examination, their diagnosis reflects individual
perspectives in the processing, assigning of importance, and categorizing of medical information. As diagnostic
criteria increase in their subjectivity, diagnoses between physicians become increasingly discordant.
With the escalating incidence of melanoma now exceeding the rates of increase of all other major cancers,4 the
diagnosis of cutaneous melanocytic lesions exemplifies the challenges physicians face when interpreting and
classifying medical data. The diagnosis of cutaneous melanocytic lesions relies on a pathologist’s visual assessment
of biopsy material on microscopic slides. The reliability and predictive values of the diagnostic criteria used for these
lesions have never been established with rigorous standards. Previous studies have suggested high levels of
diagnostic discordance among pathologists in the interpretation of melanocytic lesions,5 6 7 8 alluding to the potential
for both overdiagnosis and underdiagnosis,4 9 yet these older studies were limited in number of specimens and
pathologists. Thus there is a critical need to evaluate the current quality of diagnostic practices in this specialty and
consider the impact at the population level.
We evaluated the reproducibility and accuracy of melanocytic lesion diagnoses provided by a broad spectrum of
practicing pathologists in the USA. Reproducibility was assessed by intraobserver and interobserver concordance
rates. Accuracy was evaluated using three different reference diagnoses. We then estimated how diagnostic variability
affected accuracy from the perspective of an adult patient in the USA. These evaluations are overdue because of the
therapeutic ramifications, emotional and physical burdens of diagnosis, and utilization of healthcare resources.

Methods

Study procedures included recruitment of pathologists in several US states who interpret melanocytic lesions, a
baseline survey, independent interpretations of melanocytic lesions at two time points, a personalized feedback
module, and a post-interpretation survey. Detailed information about development of the cases, participant
recruitment, and diagnostic classification is provided elsewhere.10 11 12 13 14
Histology form and mapping scheme
We gathered assessment and recommendations on each case using a standardized online histology form and then
classified the diverse terms using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATHDx) histology form.13 This tool organizes pathologists’ diverse descriptive terms of melanocytic skin lesions into five
diagnostic classes, with suggested treatment recommendations (table 1). Example diagnostic terms for each class (and
suggested treatment recommendations, all provided under the assumption that specimen margins are positive)
include: class I, nevus or mild atypia (no further treatment margin required); class II, moderate atypia (consider
narrow but complete repeat excision margin <5 mm); class III, severe atypia or melanoma in situ (repeat excision
with ≥5 mm but <1 cm margins); class IV, pT1a invasive melanoma (wide excision ≥1 cm margin); and class V,
≥pT1b invasive melanoma (wide excision ≥1 cm with possible additional treatment, such as sentinel lymph node
biopsy and adjuvant therapy).
Biopsy case development
Cutaneous melanocytic lesions from shave, punch, and excisional specimens were included.13 14 16 We selected
cases using stratification based on patient age (20-49 years, 50-64 years, ≥65 years) and medical chart documentation
of the original diagnosis. Three experienced dermatopathologists with recognized expertise in cutaneous melanocytic
lesions (RLB, DEE, MWP) prepared and independently reviewed new haematoxylin and eosin stain glass slides for
each case, followed by consensus review using a modified Delphi approach.14 17 The final 240 cases had
intentionally higher proportions in classes II-V than are typically encountered in practice: 10.4% (n=25) in class I,
15.0% (n=36) in class II, 25.0% (n=60) in class III, 24.2% (n=58) in class IV, and 25.4% (n=61) in class V. We
assembled the 240 cases into five sets of 48 cases. All participants interpreted 48 cases in phase 1. In phase 2, those
who agreed to alternatively participate in a substudy of digital whole slide imaging interpreted a subset of 36 of their
original 48 cases; otherwise, participants who declined the substudy interpreted the same 48 cases as in phase 1 (see
figure 1 in web appendix).
Pathologist identification, recruitment, and baseline characteristics
We identified potential participants using publicly available information from 10 US states (CA, CT, HI, IA, KY, LA,
NJ, NM, UT, and WA). Pathologists were invited by email, postal mail, and telephone. Eligible participants had
completed their pathology residencies and/or fellowships, interpreted cutaneous melanocytic lesions within the
previous year, and expected to interpret cutaneous melanocytic lesions for the next two years. Participants completed
a baseline survey assessing their personal and clinical practice characteristics.10 12 To compare characteristics among
participants and non-participants, we obtained additional information from Direct Medical Data.18
Interpretations by participants
We stratified randomization to specific slide sets by pathologists’ clinical expertise, which was dichotomized
according to possession of one or more of the following self reported characteristics on the baseline survey:
fellowship trained or board certified in dermatopathology; considered by colleagues to be an expert in melanocytic
lesions; or 10% or more of usual caseload included cutaneous melanocytic lesions.
Slides were presented in a random order to each participant. Participants were provided with the patient’s age, biopsy
type, and anatomic location of biopsy site. Standardized diagnostic definitions or educational materials were not
provided. We asked the pathologists to assume that the single glass slide was representative of the entire lesion, and
that the margin was involved (irrespective of whether it involved the biopsy margin or not). Participants were asked
to complete their interpretations within one week.
Pathologists provided their diagnoses using the online histology data collection form, which contained 56 different
terms13 (see table 1 in web appendix). For each case we summed and averaged the total number of different diagnosis
terms used to describe that case in phase 1. Eight or more months after completing initial interpretations in phase 1,

pathologists assessed the same cases a second time in phase 2. For the second phase, we presented the cases in a
different randomly assigned order for each participant; pathologists were not informed that these were the same cases.
As the same glass slide was used for each case, only one participant could have the test sets at a time. Thus, more
than three years were required for data collection from all participants on the baseline survey, the phase 1 and 2 data
interpretations, and the post-interpretation survey.
Pathologists were offered up to 20 hours of free category 1 Continuing Medical Education credits for completing the
baseline survey, the interpretations, a web based educational feedback module, and a brief post-interpretation survey.
In the post-interpretation survey, we asked participants whether standardized classification for melanocytic lesions
would improve patient care, and their likelihood of adopting it in practice.
Statistical analyses
We calculated both interobserver and intraobserver concordance rates. For interobserver concordance, we considered
all pairs of interpretations of the same case by two different pathologists in phase 1 and calculated the proportion of
those pairs where interpretations were in the same diagnostic class. The 187 pathologists in phase 1 provided 6814
participant pairs reading the same test set and 48 case interpretations per pair, resulting in 327 072 total pairwise
assessments of two pathologists independently interpreting the same glass slide for a case. Confidence intervals for
interobserver rates used centiles of the bootstrap distribution, where resampling of pathologists was performed 3000
times.
For intraobserver concordance, we calculated the proportion of phase 1 interpretations where the same slide received
an interpretation in the same diagnostic class by the same pathologist in phase 2. Confidence intervals for
intraobserver concordance rates used a logit transformation and robust standard error that accounted for clustering at
pathologist level. As a precaution, we created back-up test sets utilizing adjacent serial sections reviewed by the
consensus panel for comparability. One of the five test sets was lost in shipment during phase 2. The intraobserver
phase 1 or 2 reproducibility for the 11 participants who interpreted the back-up test set in phase 2 was similar to that
of the 10 participants reading the original set in both phases. Change in overall reproducibility when excluding the
former was negligible (3418/5112, 66.9% to 3116/4644, 67.1%).
To measure accuracy, we compared the pathologists’ diagnoses on each case with one of three reference diagnoses.
While our primary reference diagnosis was the consensus reference diagnosis reached by the aforementioned panel of
three experienced dermatopathologists, two additional reference diagnoses were explored. We defined an experienced
participant reference diagnosis based on the most frequent classification (mode) of each case by the board certified
and/or dermatopathology fellowship trained participants (74 of the 187 pathologists completing phase 1). For 12
cases, a bimodal distribution was observed, and we chose the more severe diagnosis. The third reference standard was
the community reference diagnosis defined by the most frequent diagnosis (mode) of each case by all participating
pathologists. In three of the 240 patient cases, a bimodal distribution occurred in the community reference diagnosis,
and we chose the more severe diagnosis.
Primary accuracy outcome measures included over-interpretation, under-interpretation, and overall concordance rates
with the reference diagnoses. We defined over-interpretation as diagnosing cases at a higher diagnostic class than the
reference diagnosis, and under-interpretation as diagnosing cases at a lower diagnostic class than the reference
diagnosis. Interpretations in agreement were those in which the diagnostic classes assigned by the participants and the
reference diagnoses were concordant. Confidence intervals accounted for both within participant and across
participant variability. We also investigated variability in participant interpretations of each case separately to assess
whether variability was limited to a subset of cases.
Population estimates
We estimated the probability that a pathologist’s interpretation of a skin biopsy slide at the US population level would
be confirmed if reviewed by a consensus based reference standard derived from three experienced
dermatopathologists interpreting the same slide. For example, if one slide from a patient’s skin biopsy is initially
interpreted as melanoma in situ (MPATH-Dx class III), how likely is this patient to obtain the same diagnosis if a
panel of three experienced pathologists provides a consensus interpretation of the same slide?

This calculation required reweighting the prevalence of skin biopsy classifications to reflect the distribution found in
clinical practice compared with the distribution in our study, which included more of the cases that were intermediate
and more difficult to interpret. Recent results about the prevalence of skin pathology diagnoses of melanocytic lesions
from a large health plan in the Pacific Northwest of the USA (J P Lott, personal communication, 2017) were
employed, where the prevalence values were 83.1% (15 558/18 715) for class I, 8.3% (1548/18 715) for class II, 4.5%
(842/18 715) for class III, 2.2% (405/18 715) for class IV, and 1.9% (362/18 715) for class V (see table 3 in web
appendix). In comparison, the prevalence values in our study were 10% (25/240) for class I, 15% (36/240) for class
II, 25% (60/240) for class III, 24% (58/240) for class IV, and 25% (61/240) for class V (see table 2 in web appendix).
The method for calculating the probabilities using Bayes’ theorem have previously been described19 and is a standard
algorithm for the calculation of predictive values from accuracy and prevalence estimates. The method essentially
involves reweighting case interpretations by the ratio of the population prevalence to the study prevalence of the
diagnostic category assigned to that case by the reference.
Patient involvement
This work was inspired by the first author’s experience as a patient undergoing a skin biopsy, which resulted in three
different independent interpretations, ranging from benign to invasive melanoma. No other patients were involved in
setting the research question or the outcome measures, nor were they involved in developing plans for recruitment,
design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. We
look forward to collaborating with both patient and professional groups to disseminate our findings broadly, with the
goal of increasing understanding of variability in diagnostic interpretation and ultimately to improve patient care.

Results
Pathologist participation and characteristics
Of 301 eligible participants, 207 (69%) were enrolled and 187 (62%) completed independent phase 1 interpretations.
There were no statistically significant differences in mean age, time spent in direct medical care, or number practicing
in a community of 250 000 or more people between the 207 eligible pathologists who agreed to participate and the
pathologists who were eligible but declined (data not shown, all comparisons P≥0.05). Among eligible responders, a
slightly higher percentage of women (84/111, 76%) than men (123/190, 65%; P=0.048) participated.
Of those completing phase 1, 99 participants agreed to participate in the aforementioned substudy of digital whole
slide imaging in phase 2, and were randomized to interpret glass (n=49) or digital (n=50) subsets of 36 cases (see
figure 1 in web appendix). Those who declined the substudy (n=74) received their same set of 48 glass slides for
phase 2 interpretations. A total of 118 participants completed phase 2 in the glass format and were retained for
intraobserver analyses.
Table 2 shows the characteristics of the 187 participating pathologists. Most were men (n=114, 61%), aged 50 or
more years (n=100, 54%), not affiliated with an academic medical center (n=134, 72%), and reported 10 or more
years of experience in interpreting melanocytic skin lesions (n=113, 60%). All pathologists interpreted melanocytic
skin lesions in their clinical practice as a requirement to participate; for 36 (19%) these melanocytic lesions
represented more than a quarter of their caseload. Though 129 (69%) reported that interpreting melanocytic skin
lesions made them more nervous than other types of pathology, 161 (86%) also reported being moderately to
extremely confident in their assessments of melanocytic lesions.
Diagnostic terms for melanocytic lesions
The 240 biopsy cases were divided into five test sets (A to E). Each test set in phase 1 had 48 cases and each test set
in phase 2 had 36 or 48 cases, as previously described. The 187 pathologists were randomized to a test set, with the
final number of pathologists interpreting each test set in phase 1: test sets A, n=39; B, n=36; C, n=38; D, n=36; and E,
n=38. Thus 36 to 39 different pathologists in phase 1 independently interpreted the same original glass slide for each
skin biopsy case, with each pathologist viewing the same glass slide when interpreting a case.
The pathologists used diverse diagnostic terms to classify the melanocytic proliferations. The mean number of
diagnostic terms applied for each case in phase 1 was 10 (SD 4, range 2-21). For example, one case independently
interpreted by 36 study pathologists using their own microscopes to view the same glass slide had 18 different terms
ascribed to it for the diagnosis (fig 1). Despite the striking variation in terminology, the suggested treatment for many

of these diagnostic labels using Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx)
would be the same, highlighting the importance of the MPATH-Dx classification tool to organize extant nonstandardized diagnostic terminology into a smaller number of simpler categories, which range from class I (eg,
benign melanocytic lesions) to class V (≥pT1b invasive melanoma).
Reproducibility of diagnoses
Intraobserver data were assessed for 118 pathologists based on phase 1 and 2 interpretations of the same cases at least
eight months apart (table 3). Cases interpreted in phase 1 as class I (eg, banal or mildly dysplastic nevus) and class V
(eg, ≥pT1b invasive melanoma) were likely to receive a diagnosis in the same class when interpreted by the same
pathologist in phase 2 (77% (1155/1506) and 83% (852/1031), respectively). Pathologists’ reproducibility when
diagnosing the same case twice was lower for cases initially interpreted as class II (eg, moderately dysplastic nevus;
35% (227/644)), class III (eg, melanoma in situ; 60% (653/1091)), and class IV (eg, early stage invasive melanoma;
63% (531/840)).
As expected, pathologists were more consistent with their own initial diagnosis of a case when viewing a glass slide a
second time than when their diagnoses were compared with peers independently interpreting the same glass slide.
Intraobserver concordance rates were consistently higher than the interobserver concordance rates (table 4). For
example, the intraobserver and interobserver concordance rates for cases interpreted in phase 1 as class IV were 63%
(95% confidence interval 59% to 67%) and 46% (43% to 49%), respectively.
Accuracy of diagnoses
Table 5 and figure 2 show the accuracy of the 187 pathologists’ phase 1 interpretations for each diagnostic class
based on the consensus reference diagnosis. Concordance with the reference was 92% (862/935) for class I, 25%
(331/1342) for class II, 40% (908/2247) for class III, 43% (928/2169) for class IV, and 72% (1646/2283) for class V.
Figure 3 shows a comparison of the pathologists’ over-interpretation and under-interpretation rates when considering
the consensus reference panel and the two additional reference diagnoses. The discordance rates were more than 40%
for cases in classes II, III, and IV regardless of the method used to define the reference standard.
Population estimates
Most melanocytic skin biopsy lesions in a clinical setting are of benign MPATH-Dx class I lesions, whereas the
composition of our test set was heavily weighted towards MPATH-Dx classes II-V lesions. We describe at a
population perspective how the diagnostic variability noted in this testing situation might affect accuracy (fig 4, table
3 in web appendix). Overall, 82.8% (95% confidence interval 81.0% to 84.5%) of skin biopsy diagnoses for
melanocytic lesions would be verified by consensus of three experienced dermatopathologists, with 8.0% (6.2% to
9.9%) of biopsies over-interpreted by the initial pathologist and 9.2% (8.8% to 9.6%) under-interpreted. Of cases
interpreted in classes II, III, and IV, we estimate that only 26%, 35%, and 51%, respectively would be confirmed by
the consensus reference diagnosis, whereas the numbers are 92% for class I and 78% for class V (see table 3 in web
appendix). Of patients classified in categories IV or V (eg, with invasive melanoma) by study pathologists we
estimate from table 3 in the web appendix that 16% (52.4/324.1) would be reclassified downward to benign
categories I or II by the experienced consensus panel. Of patients classified in categories I or II by study pathologists
we estimate that 0.5% (41.3/8186.9) would be classified in categories IV or V by the experienced consensus panel.
Post-interpretation survey
Most pathologists (96%) thought it somewhat to very likely that patient care would be improved by the use of a
standardized taxonomy such as the MPATH-Dx tool in the diagnosis of melanocytic skin lesions. Nearly all
participants (98%) also stated that they would likely adopt a standardized taxonomy in their own clinical practice if
available.

Discussion
This study highlights challenges and also limitations in the diagnosis of melanocytic skin lesions by current
practicing pathologists. The highest levels of accuracy were attained for class I benign nevi (92%) and class V high
stage invasive melanoma (72%); these cases are at the polar ends of the histopathologic spectrum. Interpretations for
cases in the middle of the spectrum had noticeably lower accuracy, as less than 50% of the diagnoses were in

concordance with the reference diagnoses; class II, moderate dysplastic nevus (25%); class III, melanoma in situ
(40%); and class IV, early stage invasive melanoma (43%). Pathologists’ interpretations of the same case on two
occasions also lacked reproducibility for cases in the middle of the spectrum. This low level of diagnostic precision is
of clinical concern. Although diagnostic discordance has been described in other areas of clinical medicine,20 21
including pathologists diagnosing breast biopsies22 and radiologists interpreting mammograms,23 the findings
reported here are more pronounced than in other disciplines of medicine.
Comparison with other studies
The results of this large study strongly validate the conclusions from smaller studies that histological diagnoses of
melanocytic lesions can vary among pathologists. Previous studies were constrained by small numbers of cases (eg,
≤20),6 24 25 26 non-randomly selected cases,27 28 29 30 31 32 33 34 35 36 37 narrow disease spectrum of cases,5 7 8 25
26 27 29 32 35 36 38 39 40 41 42 43 44 45
smaller numbers of physicians (eg, ≤10),6 7 8 24 25 27 30 34 35 36 37 38 39 40 41
42 44 46 47 48
or exclusive testing of expert pathologists.5 7 8 16 30 34 35 37 38 39 40 41 42 47 In contrast, our study is
the most extensive evaluation to date. We selected 240 cases from the full histopathologic spectrum and enrolled 187
practicing pathologists from diverse geographic locations and clinical settings. Unique to our study are estimates of
intraobserver reproducibility, as well as accuracy defined by three different reference diagnoses and presentation of
the impact of diagnostic variability at a US population perspective.
Strengths and limitations of this study
In the absence of a biological reference standard for diagnosing melanocytic lesions, our analytic approach is
strengthened by the use of three reference standards to estimate accuracy. Our reference standard based on the
consensus of three experienced dermatopathologists would be considered ideal in clinical practice. In addition, we
provided sensitivity analyses based on two other reference standards: the majority diagnosis of participating board
certified or fellowship trained dermatopathologists, and a community reference based on the mode of all study
pathologists. As some pathologists may have participated in the study to improve their own performance, the
community reference may not be ideal. Although results differed by reference standard, accuracy was low for classes
II, III, and IV cases, regardless of the reference standard used.
Evaluating diagnostic accuracy requires research methods and a study setting that deviates from normal clinical
practice. While many skin biopsy cases have only one slide available and a pathologist’s diagnosis often hinges on
one area within a slide, in clinical practice pathologists might have the opportunity to review more slides on some of
their patients. Pathologists might also be able to obtain second opinions from colleagues or request ancillary tests
such as immunohistochemical and molecular studies before rendering a diagnosis. While our study evaluated
pathologists’ independent interpretations using their own microscopes, it did not evaluate overall processes within
health systems. Ideally we would insert biopsy cases into the clinical practices of a diverse group of pathologists in a
large scale, blinded manner, yet this design would not be logistically feasible given the large number of pathologists
in our study from many diverse clinical practices and the high number of cases they each interpreted. The cases in our
study also included more lesions in classes II-V relative to class I than is typical of clinical practice, thus the
importance of our population perspective results.
Clinical and policy implications
Disease classification systems often evolve from examination of prototypical cases by experts in the specialty and are
then disseminated to a broader range of practitioners on the full breadth of disease in clinical practice. Without
validation of extant diagnostic criteria that are applied to the millions of skin biopsies performed annually, present
diagnoses may not reliably or accurately distinguish biologically important differences.
Given the striking array of diagnostic terms used by practicing pathologists when interpreting the same melanocytic
lesion, we recommend further studies of a simple, management oriented classification system, such as the
Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) system used in this study.13
Most participating pathologists thought patient care would be improved through use of such a simplified taxonomy.
Thus, reducing more than 50 terms currently used into a smaller number of classes may improve communication
between the pathologist and the patient’s primary clinician. With patients increasingly reading their own pathology
reports, often through secure electronic portals, increased clarity is also important.49 50 The MPATH-Dx

classification system will likely require further examination and revisions, given the low levels of reproducibility and
accuracy for cases in the middle of the histopathologic spectrum, and studies of education in the definitions of these
subjective categories are needed.
We also recommend transparency and acknowledgement of the inherent limits of our ability to classify melanocytic
lesions. Communicating the degree of diagnostic uncertainty is an important part of professional practice, with
reports showing that 71% of consultations between clinicians and patients include verbal expressions of
uncertainty.51 Pathology reports often include phrases describing uncertainty of the diagnosis, yet interpretation of
these phrases varies widely.52 National guidelines on phraseology in pathology reporting have long been suggested.53
We propose adding standardized statements to pathology reports reminding readers that melanocytic lesions are
challenging to interpret and that variability exists among pathologists in interpretation, especially in the middle
diagnostic classes. When similar evidence summary statements were added to radiology reports of spine imaging,
fewer narcotics were prescribed by physicians receiving the reports.54 The impact of adding such disclaimers on
clinical care and also on malpractice lawsuits should be studied.
Finally, reliable and objective techniques need to be developed and validated to support pathologists’ visual
assessments of melanocytic lesions. We hope that future systems using digital whole slide imaging platforms to
obtain second opinions or molecular analysis of skin biopsies can be developed and evaluated that may lead to more
definitive classification of melanocytic lesions.55 56
Conclusion
Our study emphasizes persistent difficulties with classifying medical data based on subjective interpretations. In this
large study, diagnoses of melanoma in situ and early stage invasive melanoma (pT1a according to the American Joint
Committee on Cancer seventh edition cancer staging manual), together more common than all other stages of
melanoma combined, were neither reproducible nor accurate. Efforts to improve clinical practice should include
simplification of terminology by use of a standardized classification system, acknowledgment of the extant
uncertainty of specific diagnoses in pathology reports, and development of more sophisticated diagnostic tools to
support pathologists.
What is already known on this topic
Millions of skin biopsy samples are obtained each year
A pathologist’s visual interpretation is the cornerstone for diagnosing melanocytic lesions, including
melanoma, yet previous studies have suggested variability among pathologists in their diagnoses
What this study adds
Diagnoses within the disease spectrum from moderately dysplastic nevi to early stage invasive melanoma
are neither reproducible nor accurate
These limitations in histological diagnosis emphasize the need for supplemental reporting paradigms to
convey observer derived opinions about diagnostic uncertainty, perceived risk for disease progression, and
suggested management
Use of a standardized classification format employing unambiguous language and acknowledging
uncertainty in pathology reports might reduce the potential for miscommunication and management errors
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Figures and Tables

Table 1
Summary of MPATH-Dx reporting schema for classification of melanocytic skin lesions into five diagnostic
categories
MPATH-

Perceived risk for

Dx class

progression

0

Incomplete study due to

Suggested intervention*

Examples

Repeat biopsy or short term follow-up

NA

No further treatment

Common melanocytic nevus;

sampling or technical
limitations
I

Very low risk

blue nevus; mildly dysplastic
nevus
II

Low risk

Narrow but complete excision (<5 mm)

Moderately dysplastic nevus; Spitz nevus

III

Higher risk. Greater need

Complete excision with at least 5 mm but <1 cm

Severely dysplastic nevus;

for intervention

margins

melanoma in situ; atypical
Spitz tumor

IV
V

Substantial risk for local or Wide local excision with ≥1 cm margins

Thin, invasive melanomas (eg,

regional progression

pT1a†)

Greatest risk for regional

Wide local excision with ≥1 cm margins.

Thicker, invasive melanomas

and/or distant metastases

Consideration of staging sentinel lymph node biopsy,

(eg, pT1b, stage 2 or greater†)

adjuvant therapy

*Assuming representative sampling of lesion.
†According to American Joint Committee on Cancer seventh edition cancer staging manual.15

Table 2
Self reported characteristics of participating pathologists who completed the baseline survey and phase 1
interpretations (n=187)

Physician characteristics

No (%)

Demographics
Age (years):
<40

31 (17)

40-49

56 (30)

50-59

63 (34)

≥60

37 (20)

Sex:
Female

73 (39)

Male

114 (61)

Training and experience
Affiliation with academic medical centre:
No

134 (72)

Yes, adjunct or affiliated

34 (18)

Yes, primary appointment

19 (10)

Residency specialty:
Anatomic or clinical pathology

168 (90)

Dermatology

15 (8)

Both dermatology and anatomic or clinical pathology

4 (2)

Training:
Board certified or fellowship trained in dermatopathology*

74 (40)

Other board certification or fellowship training†

113 (60)

Years interpreting melanocytic skin lesions:
<5

29 (16)

5-9

45 (24)

10-19

57 (30)

≥20

56 (30)

Per cent of caseload interpreting melanocytic skin lesions:
<10

79 (42)

10-24

72 (38)

25-49

28 (15)

≥50

8 (4)

Average No of melanoma cases (melanoma in situ and invasive melanoma) interpreted each month:
<5

82 (44)

5-9

47 (25)

≥10

58 (31)

Open in a separate window
*Consists of physicians with single or multiple fellowships that include dermatopathology, and physicians with single or multiple
board certifications that include dermatopathology.
†Includes fellowships or board certifications in surgical pathology, cytopathology, or hematopathology.

Fig 1 Diagnostic terms given to example case by 36 pathologists who each independently interpreted the same glass slide (top image
5× magnification, bottom image 10× magnification)

Table 3
Intraobserver concordance of 118 pathologists’ interpretations of melanocytic skin biopsy lesions of the same
case at phase 1 and phase 2 at least eight months apart*

Phase 1 diagnosis

Phase 2 diagnosis (No of paired interpretations)
Class I Class II Class III Class IV Class V Total

Intraobserver concordance† % (95% CI)

Class I

1155

188

119

27

17

1506

77 (73 to 80)

Class II

170

227

182

37

28

644

35 (31 to 39)

Class III

91

120

653

169

58

1091

60 (56 to 63)

Class IV

20

37

147

531

105

840

63 (59 to 67)

Class V

14

16

44

105

852

1031

83 (80 to 85)

1450

588

1145

869

1060

5112

67‡ (65 to 69)

Total

Numbers of diagnostic interpretations with intraobserver agreement are emboldened.
*Concordance rates are influenced by case composition, which included larger proportions of cases in classes II-V than would
typically be encountered in practice.
†Denominator is phase 1 interpretations and numerator is phase 2 assessments that agreed with phase 1 interpretation. Does not
include participants who reviewed glass slides in phase 1 and digital images in phase 2.
‡Average κ for intraobserver agreement across participants is 0.57.

Table 4
Interobserver concordance of pathologists’ interpretations of melanocytic skin biopsy lesions. Pairwise
comparison of interpretations by 187 participating pathologists in phase 1. Diagnoses for all possible ordered
pairs of participants reading the same glass slide are included*

First pathologist’s
interpretation

Class I
Class II
Class III

Second pathologist’s interpretation
Class

Class

Class

Class

Class

I

II

III

IV

V

15 082

11 223

2993

1773

10 366

11 028

3974

1903

11 028

31 326

12 675

4494
8854

64
122
15
082
11
223

Class IV

2993

3974

12 675

22 334

Class V

1773

1903

4494

8854

42 353

70 746

50 830

Total

95
193

Interobserver concordance % (95%
Total
95 193
42 353
70 746

CI)

71 (69 to 73)
25 (22 to 27)
45 (42 to 47)

50 830

46 (43 to 49)

50 926 67 950

77 (75 to 79)

67 950

327
072

55† (53 to 56)

Numbers of interpretations with agreement are emboldened.
*Average pairwise agreement is an unweighted average across all participant pairs. The number of first pathologist interpretations
for a given diagnostic class varies across pairs. Concordance rates are influenced by case composition, which included larger
proportions of cases in classes II-V than would typically be encountered in practice. There are 6814 distinct order participant pairs
×48 case interpretations per pair yielding 327 072 interpretations.
†Average κ for interobserver agreement across all participant pairs is 0.42.

Table 5
Accuracy of 187 participating pathologists’ when phase 1 interpretations are compared with the consensus
reference diagnoses*
Consensus reference
diagnosis†

Study pathologists’ interpretation
Class Class Class

Class Class

Total

% Concordance with reference

interpretations

diagnosis (95% CI)

I

II

III

IV

V

(No)

Class I

862

50

19

3

1

935

92 (90 to 94)

Class II

843

331

131

26

11

1342

25 (22 to 28)

Class III

695

520

908

113

11

2247

40 (37 to 44)

Class IV

150

176

717

928

198

2169

43 (39 to 46)

Class V

68

87

161

321

1646

2283

72 (69 to 75)

2618

1164

1936

1391

1867

8976

Total

*Concordance in interpretation is emboldened.
†Reference diagnosis was obtained from consensus of three experienced dermatopathologists.

Open in a separate window
Fig 2 Participant interpretive variation on each of 240 cases, with cases organized based on the MPATH-Dx consensus reference
diagnosis class

Open in a separate window
Fig 3 Comparison of accuracy (discordance rates of over-interpretation rate and under-interpretation rate) by all three reference
diagnoses

Open in a separate window
Fig 4 Population level predicted proportions of cutaneous melanocytic biopsy interpretations that would be verified by the consensus
reference panel or would be classified as over-interpretations or under-interpretations
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